SQZ Biotech, whose initial application of cell-squeezing technology to enhance production of antigen presenting cells for immunotherapy was a KI Frontier Research Program spin-out, recently announced the expansion of its partnership with Roche Pharmaceuticals. The combination of the startup's “CellSqueeze” microfluidic device and Roche's clinical oncology expertise will accelerate the development of cell-based immunotherapies for cancer, the first of which is expected to enter clinical trials in mid-2019. A recent paper in PNAS compares the use of cell squeezing to electroporation for intracellular delivery of immune engineering agents. SQZ CEO and former KI postdoc Armon Sharei spoke with MIT News about the goals and history of the company's groundbreaking technology.